Status: Recruiting
YN001-004 in Patients With Coronary Atherosclerosis in Australia
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
Participants needed: 24
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing Inno Medicine Co., Ltd.Updated: Feb 17, 2026Locations: 7
Eligibility criteria
Fully understand the purposes, features, and methods of the study, and sign the... [+4]
Prior treatment with other investigational drug(s) within 30 days or 5 half-live... [+27]